Saturday 17 October 2026
Export CTMX’s income statement to Excel — free account
CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.
2.27
0.14
−5.81%
Follow CTMX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 6 | 2 | 2 | 5 | 2 | 3 | 3 | 5 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.71 | 0.00 |
P/S ratio |
25.80 | 11.29 | 10.57 | 6.55 | 3.01 | 7.44 | 1.99 | 1.23 | 0.63 | 7.71 |
Altman Z-Score |
0.75 | 1.45 | 0.67 | (1.07) | (0.59) | (2.28) | (4.39) | (4.19) | (5.56) | 0.92 |
Altman Z″-Score (non-manufacturers) |
0.80 | 3.05 | 2.02 | (1.80) | (0.75) | (3.80) | (9.78) | (11.22) | (16.14) | (10.12) |
P/FCF ratio |
0.00 | 4.79 | 0.00 | 0.00 | 102.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
200.45 | 36.76 | (21.89) | (12.78) | (17.34) | (8.90) | (75.98) | (5.68) | (4.37) | (25.28) |
Beneish M-Score |
(1.08) | (1.75) | (2.58) | 0.21 | 29.00 | (1.81) | 26.16 | (1.25) | 2.28 | (1.09) |
P/B ratio |
4.95 | 11.57 | 4.81 | 7.37 | 6.07 | 0.00 | 0.00 | 0.00 | 0.00 | 5.93 |
Price to Tangible BV |
5.12 | 12.01 | 4.90 | 7.71 | 6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 |
EV/Sales |
13.70 | 6.07 | 3.24 | 1.45 | (0.11) | (0.64) | (1.57) | (0.45) | (0.07) | 5.97 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.21 | 0.85 | 3.90 | 0.00 | 0.00 |
EV/Operating CF |
(101.45) | 2.55 | (2.56) | (0.59) | (2.03) | 0.20 | 0.76 | 0.82 | 0.11 | (6.01) |
EV/FCF |
(49.60) | 2.57 | (2.43) | (0.58) | (3.62) | 0.20 | 0.74 | 0.80 | 0.11 | (6.00) |
Quick Ratio |
5.15 | 6.28 | 4.46 | 3.46 | 3.14 | 3.93 | 1.50 | 1.14 | 1.21 | 2.98 |
Current Ratio |
5.26 | 6.36 | 4.55 | 3.54 | 3.21 | 3.98 | 1.55 | 1.17 | 1.25 | 3.09 |
Net Debt/EBITDA |
3.24 | 8.46 | 5.61 | 2.65 | 6.76 | 2.67 | 1.92 | 14.88 | (4.69) | 5.91 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.82% | 0.89% | 1.07% | 1.56% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.06 | 0.06 | (7.88) | (0.05) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.08 | 0.24 | 0.14 | 0.14 | 0.29 | 0.11 | 0.18 | 0.44 | 0.86 | 0.56 |
Operating CF/Net income |
0.03 | (3.95) | 0.89 | 1.37 | (0.16) | 1.03 | 1.12 | 98.48 | (2.71) | 3.71 |
Capex/Depreciation |
(0.63) | (0.77) | (20.70) | (9.28) | (0.99) | (0.54) | (0.73) | 0.16 | 0.09 | 0.27 |
Interest Coverage |
(24.57) | (17.30) | (10.19) | (13.26) | (26.47) | (455.07) | (60.39) | — | — | — |
| (57.59%) | (58.09%) | (84.28%) | (112.35%) | (65.17%) | (469.64%) | 230.41% | 0.85% | (133.06%) | (41.34%) | |
| (29.72%) | (14.44%) | (19.80%) | (25.61%) | (9.40%) | (33.20%) | (33.09%) | (0.25%) | 19.77% | (14.97%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(37.57%) | (12.99%) | (23.87%) | (45.42%) | (14.30%) | (48.61%) | (110.89%) | (1.84%) | 132.79% | (20.66%) |
Average Days of Receivables |
56.12 | 51.67 | 0.60 | 0.08 | 2.90 | 7.73 | 247.07 | 12.38 | 8.20 | 9.64 |
Research and Development Expense of Revenue |
363.99% | 128.84% | 174.56% | 228.95% | 112.53% | 306.05% | 210.01% | 76.75% | 60.38% | 90.19% |
Selling, General and Administrative Expense of Revenue |
132.11% | 35.75% | 56.32% | 63.95% | 35.90% | 104.95% | 80.60% | 29.66% | 21.52% | 39.16% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
67.11% | 15.76% | 28.37% | 33.22% | 14.73% | 35.29% | 24.69% | 8.46% | 5.55% | 8.27% |
Graham Net Nets |
0.17 | 0.08 | 0.19 | 0.03 | 0.05 | (0.11) | (1.03) | (0.53) | (0.16) | 0.16 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.54 | 5.99 | 0.54 | 0.00 | 0.00 |
Earnings Yield |
(15.13%) | (5.42%) | (13.25%) | (27.20%) | (10.69%) | (42.01%) | (75.82%) | (1.18%) | 36.89% | (0.97%) |
Free Cash Flow Yield |
(1.07%) | 20.87% | (12.61%) | (38.22%) | 0.98% | (43.43%) | (106.32%) | (45.60%) | (99.50%) | (12.90%) |
Revenue per Share |
0.42 | 1.93 | 1.43 | 1.27 | 2.17 | 0.58 | 0.81 | 1.37 | 1.64 | 0.55 |
Operating CF per Share |
(0.06) | 4.58 | (1.81) | (3.10) | 0.11 | (1.86) | (1.69) | (0.76) | (1.02) | (0.55) |
Capex per Share |
(0.06) | (0.04) | (0.09) | (0.08) | (0.05) | (0.03) | (0.03) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.11) | 4.54 | (1.90) | (3.18) | 0.06 | (1.88) | (1.71) | (0.77) | (1.02) | (0.55) |
Cash per Share |
5.02 | 10.07 | 10.47 | 6.53 | 6.85 | 4.76 | 2.95 | 2.36 | 1.19 | 0.99 |
Shareholders Equity per Share |
2.17 | 1.88 | 3.14 | 1.13 | 1.08 | (0.01) | (1.30) | (0.64) | (0.01) | 0.72 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.17 | 1.88 | 3.14 | 1.13 | 1.08 | (0.01) | (1.30) | (0.64) | (0.01) | 0.72 |
Free Cash Flow |
(4.16) | 168.81 | (79.31) | (143.98) | 2.95 | (120.64) | (112.53) | (56.87) | (86.54) | (75.81) |
Working Capital |
152.38 | 327.45 | 347.57 | 217.75 | 223.09 | 232.43 | 84.49 | 27.02 | 21.53 | 97.31 |
Capital Expenditures |
(2.12) | (1.56) | (3.79) | (3.50) | (2.31) | (1.61) | (1.74) | (0.84) | (0.31) | (0.22) |
Net Current Asset Value |
67.50 | 60.85 | 119.25 | 13.17 | 15.15 | (29.57) | (109.54) | (66.30) | (13.68) | 91.36 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.21 | 0.83 | 7.05 | 0.00 | 0.00 |
Capex to Sales |
0.14 | 0.02 | 0.06 | 0.06 | 0.02 | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.48 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.77 | 0.48 | 0.03 | 0.05 | 0.34 | 0.50 | 0.47 | (1.32) | (1.44) | (0.64) |
Cash ROIC |
(1.60%) | 38.02% | (13.99%) | (41.13%) | 0.80% | (39.12%) | (100.49%) | (44.76%) | (86.40%) | (32.11%) |
Accounts Receivable Turnover |
11.21 | 11.50 | 11.63 | 1,045.25 | 247.50 | 46.99 | 2.89 | 5.14 | 42.27 | 29.79 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.34 | 6.23 | 5.12 | 0.06 | 0.41 | 0.79 | 18.39 | 19.71 | 3.27 | 2.56 |
Average Payables |
5.65 | 5.40 | 4.67 | 4.65 | 3.58 | 2.91 | 2.81 | 2.13 | 1.27 | 1.19 |
Average Assets |
198.17 | 298.39 | 427.38 | 399.20 | 349.97 | 349.04 | 300.15 | 231.34 | 161.16 | 136.05 |
Average Common Equity |
102.27 | 74.19 | 100.39 | 91.00 | 50.46 | 24.67 | (43.11) | (66.60) | (23.95) | 49.28 |
Columns are period end dates